Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis
- 1 February 2008
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (3), 627-638
- https://doi.org/10.1016/j.bcp.2007.09.029
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Targeting hypoxia tolerance in cancerDrug Resistance Updates, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996
- Apoptosis in Human Adenocarcinoma HT29 Cells Induced by Exposure to HypoxiaJNCI Journal of the National Cancer Institute, 1995